Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | MAP2 | P11137 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.41 |
| ▸ | PLAU | P00749 | 2/20 | 0.41 |
| ▸ | PLAT | P00750 | 2/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.41 |
| ▸ | F7 | P08709 | 2/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.41 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6118011 | 0.87 | KDM4E (0.54) | KDM4EKMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL4568256 | 0.80 | RAB9A (0.57) | KDM4EKMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL6116673 | 0.78 | TNKS (0.46) | KDM4EKMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL6117305 | 0.77 | ALDH1A1 (0.55) | KDM4EKMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL6118322 | 0.76 | RAB9A (0.64) | KDM4EKMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL4568259 | 0.71 | KDM4E (0.57) | KDM4EKMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL4568298 | 0.71 | CYP19A1 (0.55) | KDM4EKMT2AMAPTRAB9AMEN1 | |
| SCHEMBL11795033 | 0.71 | KDR (0.58) | KDM4EKMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL6117642 | 0.70 | IMPDH2 (0.43) | KDM4EKMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL4568293 | 0.70 | PDGFRB (0.42) | KDM4EKMT2AMAPTRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680120-B2 | Indole derivative or pharmaceutically acceptable salt thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| EP-2460791-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120129890-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | KDM4E 3521/4885KMT2A 2056/4885MAPT 3199/4885 |
| US-20120129890-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, ARRB1 | KDM4E 3321/4885KMT2A 2189/4885MAPT 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.